vs
Side-by-side financial comparison of Adaptive Biotechnologies Corp (ADPT) and NEUROCRINE BIOSCIENCES INC (NBIX). Click either name above to swap in a different company.
NEUROCRINE BIOSCIENCES INC is the larger business by last-quarter revenue ($805.5M vs $71.7M, roughly 11.2× Adaptive Biotechnologies Corp). NEUROCRINE BIOSCIENCES INC runs the higher net margin — 19.1% vs -18.9%, a 38.0% gap on every dollar of revenue. On growth, Adaptive Biotechnologies Corp posted the faster year-over-year revenue change (51.0% vs 28.3%). NEUROCRINE BIOSCIENCES INC produced more free cash flow last quarter ($386.0M vs $1.4M). Over the past eight quarters, Adaptive Biotechnologies Corp's revenue compounded faster (30.8% CAGR vs 25.0%).
ExpreS2ion Biotechnologies is a Danish biotechnology company specialised in the development of new vaccines and immunotherapy products based in Hørsholm, Denmark and listed on the Nasdaq First North Growth Market Sweden.
Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kyle Gano as of October 11, 2024. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine (Ingrezza) was approved in the US to treat adults with tardive dyskinesia (TD).
ADPT vs NBIX — Head-to-Head
Income Statement — Q4 2025 vs Q4 2025
| Metric | | |
|---|---|---|
| Revenue | $71.7M | $805.5M |
| Net Profit | $-13.6M | $153.7M |
| Gross Margin | 74.6% | 97.8% |
| Operating Margin | -17.8% | 26.2% |
| Net Margin | -18.9% | 19.1% |
| Revenue YoY | 51.0% | 28.3% |
| Net Profit YoY | 59.7% | 49.1% |
| EPS (diluted) | $-0.08 | $1.49 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $71.7M | $805.5M | ||
| Q3 25 | $94.0M | $794.9M | ||
| Q2 25 | $58.9M | $687.5M | ||
| Q1 25 | $52.4M | $572.6M | ||
| Q4 24 | $47.5M | $627.7M | ||
| Q3 24 | $46.4M | $622.1M | ||
| Q2 24 | $43.2M | $590.2M | ||
| Q1 24 | $41.9M | $515.3M |
| Q4 25 | $-13.6M | $153.7M | ||
| Q3 25 | $9.5M | $209.5M | ||
| Q2 25 | $-25.6M | $107.5M | ||
| Q1 25 | $-29.9M | $7.9M | ||
| Q4 24 | $-33.7M | $103.1M | ||
| Q3 24 | $-32.1M | $129.8M | ||
| Q2 24 | $-46.2M | $65.0M | ||
| Q1 24 | $-47.5M | $43.4M |
| Q4 25 | 74.6% | 97.8% | ||
| Q3 25 | 80.7% | 98.2% | ||
| Q2 25 | 69.4% | 98.4% | ||
| Q1 25 | 67.6% | 98.4% | ||
| Q4 24 | 62.0% | 98.5% | ||
| Q3 24 | 64.1% | 98.7% | ||
| Q2 24 | 55.3% | 98.4% | ||
| Q1 24 | 56.9% | 98.5% |
| Q4 25 | -17.8% | 26.2% | ||
| Q3 25 | 10.9% | 30.1% | ||
| Q2 25 | -42.5% | 21.2% | ||
| Q1 25 | -56.4% | 4.1% | ||
| Q4 24 | -71.3% | 22.6% | ||
| Q3 24 | -70.3% | 29.5% | ||
| Q2 24 | -109.6% | 24.6% | ||
| Q1 24 | -116.5% | 19.3% |
| Q4 25 | -18.9% | 19.1% | ||
| Q3 25 | 10.2% | 26.4% | ||
| Q2 25 | -43.5% | 15.6% | ||
| Q1 25 | -56.9% | 1.4% | ||
| Q4 24 | -71.0% | 16.4% | ||
| Q3 24 | -69.1% | 20.9% | ||
| Q2 24 | -107.0% | 11.0% | ||
| Q1 24 | -113.5% | 8.4% |
| Q4 25 | $-0.08 | $1.49 | ||
| Q3 25 | $0.06 | $2.04 | ||
| Q2 25 | $-0.17 | $1.06 | ||
| Q1 25 | $-0.20 | $0.08 | ||
| Q4 24 | $-0.22 | $1.00 | ||
| Q3 24 | $-0.22 | $1.24 | ||
| Q2 24 | $-0.31 | $0.63 | ||
| Q1 24 | $-0.33 | $0.42 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $70.5M | $713.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $218.8M | $3.3B |
| Total Assets | $512.7M | $4.6B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $70.5M | $713.0M | ||
| Q3 25 | $55.0M | $340.2M | ||
| Q2 25 | $43.2M | $264.0M | ||
| Q1 25 | $50.6M | $194.1M | ||
| Q4 24 | $47.9M | $233.0M | ||
| Q3 24 | $38.1M | $349.1M | ||
| Q2 24 | $59.8M | $139.7M | ||
| Q1 24 | $71.2M | $396.3M |
| Q4 25 | $218.8M | $3.3B | ||
| Q3 25 | $204.4M | $3.0B | ||
| Q2 25 | $179.7M | $2.7B | ||
| Q1 25 | $190.4M | $2.5B | ||
| Q4 24 | $202.7M | $2.6B | ||
| Q3 24 | $223.8M | $2.7B | ||
| Q2 24 | $241.6M | $2.5B | ||
| Q1 24 | $274.9M | $2.4B |
| Q4 25 | $512.7M | $4.6B | ||
| Q3 25 | $490.6M | $4.3B | ||
| Q2 25 | $496.6M | $3.9B | ||
| Q1 25 | $510.9M | $3.7B | ||
| Q4 24 | $539.4M | $3.7B | ||
| Q3 24 | $558.5M | $3.5B | ||
| Q2 24 | $584.9M | $3.3B | ||
| Q1 24 | $620.3M | $3.5B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $2.1M | $388.4M |
| Free Cash FlowOCF − Capex | $1.4M | $386.0M |
| FCF MarginFCF / Revenue | 2.0% | 47.9% |
| Capex IntensityCapex / Revenue | 0.9% | 0.3% |
| Cash ConversionOCF / Net Profit | — | 2.53× |
| TTM Free Cash FlowTrailing 4 quarters | $-48.9M | $743.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.1M | $388.4M | ||
| Q3 25 | $-7.1M | $227.5M | ||
| Q2 25 | $-12.4M | $102.0M | ||
| Q1 25 | $-28.5M | $64.8M | ||
| Q4 24 | $-12.5M | $242.5M | ||
| Q3 24 | $-27.1M | $158.0M | ||
| Q2 24 | $-17.3M | $64.6M | ||
| Q1 24 | $-38.4M | $130.3M |
| Q4 25 | $1.4M | $386.0M | ||
| Q3 25 | $-7.5M | $214.3M | ||
| Q2 25 | $-13.1M | $89.5M | ||
| Q1 25 | $-29.7M | $54.1M | ||
| Q4 24 | $-12.6M | $235.2M | ||
| Q3 24 | $-27.4M | $149.9M | ||
| Q2 24 | $-19.0M | $53.0M | ||
| Q1 24 | $-39.9M | $119.1M |
| Q4 25 | 2.0% | 47.9% | ||
| Q3 25 | -8.0% | 27.0% | ||
| Q2 25 | -22.2% | 13.0% | ||
| Q1 25 | -56.7% | 9.4% | ||
| Q4 24 | -26.5% | 37.5% | ||
| Q3 24 | -59.0% | 24.1% | ||
| Q2 24 | -44.1% | 9.0% | ||
| Q1 24 | -95.2% | 23.1% |
| Q4 25 | 0.9% | 0.3% | ||
| Q3 25 | 0.4% | 1.7% | ||
| Q2 25 | 1.1% | 1.8% | ||
| Q1 25 | 2.4% | 1.9% | ||
| Q4 24 | 0.2% | 1.2% | ||
| Q3 24 | 0.7% | 1.3% | ||
| Q2 24 | 4.0% | 2.0% | ||
| Q1 24 | 3.6% | 2.2% |
| Q4 25 | — | 2.53× | ||
| Q3 25 | -0.75× | 1.09× | ||
| Q2 25 | — | 0.95× | ||
| Q1 25 | — | 8.20× | ||
| Q4 24 | — | 2.35× | ||
| Q3 24 | — | 1.22× | ||
| Q2 24 | — | 0.99× | ||
| Q1 24 | — | 3.00× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ADPT
| Mrd Business Segment | $61.9M | 86% |
| Immune Medicine Business | $9.8M | 14% |
| Immune Medicine Service Revenue | $100.0K | 0% |
NBIX
| INGREZZA Net Product Sales | $653.8M | 81% |
| CRENESSITY Net Product Sales | $135.4M | 17% |
| Other Income | $12.6M | 2% |
| Collaboration Revenue | $7.2M | 1% |
